Jennison Associates LLC Makes New $1.11 Million Investment in Rapport Therapeutics (NASDAQ:RAPP)

Jennison Associates LLC bought a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 62,287 shares of the company’s stock, valued at approximately $1,105,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Values First Advisors Inc. bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new position in Rapport Therapeutics in the 3rd quarter worth approximately $34,000. JPMorgan Chase & Co. bought a new position in Rapport Therapeutics in the 3rd quarter worth approximately $83,000. SG Americas Securities LLC bought a new position in Rapport Therapeutics in the 3rd quarter worth approximately $101,000. Finally, MetLife Investment Management LLC bought a new position in Rapport Therapeutics in the 3rd quarter worth approximately $117,000.

Rapport Therapeutics Stock Down 4.6 %

RAPP opened at $16.75 on Friday. The company has a 50 day moving average of $17.48 and a 200 day moving average of $20.37. Rapport Therapeutics has a 12 month low of $12.09 and a 12 month high of $29.74.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.07. As a group, equities analysts forecast that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.